Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2a study investigating Deflexifol™ in combination with oxaliplatin ("DEFLOX") and bevacizumab in the 1st line treatment of unresectable metastatic colorectal cancer (mCRC) patients

Next Previous
Search
Trial Profile

A phase 1b/2a study investigating Deflexifol™ in combination with oxaliplatin ("DEFLOX") and bevacizumab in the 1st line treatment of unresectable metastatic colorectal cancer (mCRC) patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil/folinic-acid (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Aug 2023 New trial record
    • 31 Jul 2023 According to an Allarity Therapeutics media release, the company has entered into Clinical Collaboration Agreement to support clinical development of Deflexifol with DRP companion diagnostics to potentially select patients for enrollment in clinical trials.
    • 31 Jul 2023 According to an Allarity Therapeutics media release, the company plans to initiate this study in H2 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top